TB-500
TB5 · 10 mg · 2x weekly
SCIENCE • STRENGTH • LONGEVITY
Before you draw anything. Every figure in this document assumes a 10 mg vial reconstituted with 2.0 mL of bacteriostatic water. Change either number and every unit measurement here changes with it. Confirm the milligram strength printed on your vial first.
TB-500 is a synthetic fragment of Thymosin Beta-4. It acts on actin, the structural protein that lets cells move, which is the basis for its use in tissue repair and remodeling research. It is systemic rather than site-specific — injection location does not need to track the area of interest.
RECONSTITUTION
| Parameter | Value |
|---|---|
| Vial | 10 mg |
| Bacteriostatic water | 2.0 mL |
| Concentration | 5 mg/mL |
| Conversion | 50 units = 2.5 mg · 40 units = 2 mg · 1 unit = 0.05 mg |
| Route | Subcutaneous, systemic |
| Reconstituted storage | 2–8 °C, 1–2 weeks. Do not freeze. |
| Lyophilized storage | −20 °C, 12+ months |
- Let the vial and the bacteriostatic water reach room temperature.
- Swab both stoppers with alcohol and let them dry.
- Draw the planned volume of bacteriostatic water into a sterile syringe.
- Aim the stream at the inside wall of the glass, never directly at the powder.
- Roll gently for 30 to 60 seconds until fully dissolved. Never shake — shaking damages the peptide.
- Confirm the solution is clear before use.
- Label with product, concentration, and date, then refrigerate.
DOSING SCHEDULE
| Phase | Amount | Units | Frequency | Duration |
|---|---|---|---|---|
| Loading | 2.5–5 mg | 50–100 | 2x weekly | Weeks 1–4 |
| Maintenance | 2 mg | 40 | 2x weekly | Weeks 5–8 and beyond |
The stability window is the binding constraint. Reconstituted TB-500 holds only 1 to 2 weeks refrigerated — the shortest window of anything in the catalog. At 2.5 mg twice weekly a 10 mg vial covers four injections, which is about two weeks. That happens to land inside the window, but only just. Do not reconstitute more than fits a two-week run.
Notes
- Twice weekly, spaced evenly — Monday and Thursday is the common pattern.
- Site does not need to match the area of interest. TB-500 works systemically, unlike BPC-157.
- Short-term fatigue during the first one to two weeks of loading is the most commonly reported effect.
- Rotate sites across abdomen, thigh, and flank.
- Never combine with another compound in the same syringe.
Relationship to GLOW 70
GLOW 70 already contains TB-500, but at roughly 0.33 mg per daily draw — under a tenth of a standalone injury amount. The reason to run TB-500 separately is dose control, not stacking on top of GLOW. Running both means paying twice for the same compound while still sitting below the standalone range on the GLOW side.
CAUTIONS
- Active cancer or a strong cancer history. TB-500 promotes angiogenesis, and new blood vessel growth is what a tumor requires to expand. This is the principal caution.
- Active retinal vascular disease or other conditions sensitive to angiogenic signaling.
- Pregnancy or breastfeeding — no safety data exists.
- Prohibited by WADA at all times, in and out of competition.
Supplies
- U-100 insulin syringes, 0.3 mL / 30-unit. Half-unit gradations matter at these draw volumes.
- Bacteriostatic water, 10 mL bottle.
- Alcohol prep pads and a sharps container.
Record keeping
Log the date, units drawn, and site for every injection, alongside any symptoms. This catches gradual dose drift, and if something does go wrong it identifies exactly which step it started on.